Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Durvalumab Plus DOS Followed by Surgery and Adjuvant Durvalumab Plus S-1 in pMMR Gastric or GEJ Adenocarcinoma
NCT04221555Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- May 2020
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Asan Medical Center. Started May 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04221555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221555.